BeiGene Shares Rise on First Dosing of Brukinsa
Provided by
Dow Jones
By Dean Seal
American depositary receipts of BeiGene jumped after the company said the first doses of its lymphocytic leukemia treatment Brukinsa have been administered to patients in Armenia and Nepal.
The stock was up 9% at $179 in premarket trading. Shares had fallen 9% year-to-date when the market closed Tuesday.
The oncology company said Wednesday morning that the initial dosing comes as part of a three-year collaboration with a health equity nonprofit, The Max Foundation, and its own nonprofit charitable foundation to provide access to medicine in low- and middle-income countries.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 13, 2024 08:42 ET (12:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth